TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Paraneoplastic syndrome associated with gynaecological malignancy
Key Statistics
- ~8% — PNS incidence, all oncology patients
- 23% — Anti-yo positive in ovarian carcinoma
- 22 yrs — Median age, NMDAR-antibody encephalitis
Don't-miss facts
-
PNS symptoms often pre-date the cancer diagnosis – treat as a red flag for occult malignancy work-up
-
Anti-Yo PCD: 23% of ovarian carcinoma patients positive; do NOT serially monitor antibody titres (no correlation with severity); median survival 22 months
-
NMDAR encephalitis: median age 22; 65% have an ovarian teratoma – arrange pelvic ultrasound surveillance; immunotherapy >75% good outcome
-
Paraneoplastic hypercalcaemia = ectopic PTHrP, normal-to-low PTH; treat with fluids first, then bisphosphonates
-
SCCOHT: young women, SMARCA4 mutation, <1% of ovarian cancers, poor prognosis, usually hypercalcaemic
-
Struma ovarii surgery risks thyroid storm – antithyroid drugs + laparoscopic approach + careful monitoring
-
GTD hyperthyroidism driven by very high hCG (4000× less potent than TSH at receptor) – resolves with choriocarcinoma treatment
-
FIGO GTN score ≤6 = low risk, ≥7 = high risk of resistance to chemotherapy
PNS by system – quick map
Neuro: PCD (anti-Yo), encephalitis (anti-Hu, NMDAR) Endocrine: Cushing's, hypercalcaemia, hyperthyroidism
Rheum: dermatomyositis (ovarian cancer, 25%)
Abbreviation Key
- PNS — paraneoplastic syndrome
- PTH — parathyroid hormone
- PCD — paraneoplastic cerebellar degeneration
- SCCOHT — small cell carcinoma of the ovary, hypercalcaemic type
- NMDAR — N-methyl-D-aspartate receptor
- hCG — human chorionic gonadotrophin
- CDR2 — cerebellar degeneration-related protein 2
- TSH — thyroid-stimulating hormone
- MRI — magnetic resonance imaging
- GTD — gestational trophoblastic disease
- ACTH — adrenocorticotrophic hormone
- GTN — gestational trophoblastic neoplasia
- CRH — corticotrophin-releasing hormone
- FIGO — International Federation of Gynecology and Obstetrics
- PTHrP — parathyroid hormone-related protein
- IVIg — intravenous immunoglobulin
Source: Brown A et al. Paraneoplastic syndrome associated with gynaecological malignancy: a review of the evidence. The Obstetrician & Gynaecologist 2022;24:137–142. doi:10.1111/tog.12804
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).